# A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

> **NCT00320255** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 130 (actual)

## Conditions studied

- Thrombosis
- Cancer
- Pulmonary Embolism

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00320255
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2016-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00320255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00320255, "A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00320255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*